The FTSE 100 Will Always Beat You

On average, the FTSE 100 (INDEXFTSE:UKX) always beats private investors.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

stock exchangeEvery investor’s goal is to make money and increase their wealth, or at least protect their wealth. However, the majority of private investors fail to accomplish this simple goal. 

Indeed, it’s often said that many private investors underperform the market, although until recently there have been no definitive figures detailing to what degree investors actually underperform. But now we know, and the numbers are terrifying. 

Lagging the index

Over the past 20 years the FTSE 100 has risen at a rate of around 5.4% per annum, excluding fees, dividends and inflation — dividends received are likely to cancel out fees and inflation anyway. During this period, the market has seen the dotcom bubble and the financial crisis: two events that have sent the FTSE 100 surging to a high of nearly 7,000 and crashing to a low of around 3,000. 

In comparison, over the same 20-year period, according to research conducted by a number of financial institutions, the average investor has only returned 2.5% per annum including dividends. This paltry return is, in a word, shocking.

In fact, the average investor underperformed nearly every financial instrument bar one over the 20-year period studied. The only market that put in a worse performance than the average investor over this period was that Japanese stock market. Some of the instruments that performed better than the average investor over the past 20 years include: cash (3% p.a.), bonds (3% – 8% p.a.), hedge funds (8% p.a.), REITS (10% p.a.) and all emerging markets (6% – 10% p.a.).

All in all, if you include inflation, in real terms over the past 20 years the average investor has returned 0% p.a., while the FTSE 100 has returned over 5%. 

Slow and steady

Many analysts agree that the average investor underperforms the market because they trade too much. As a result, fees eat away at returns and many investors often buy high and sell low, erasing much of their capital in the process. 

So, it seems as if the best way to avoid these dismal returns and rack up a performance that is at least in line with the wider market, investors should look to tracker funds. 

It’s easy to see how a simple tracker fund can transform your portfolio. Over the past 29 years, the FTSE 100 has returned around 5.5% per annum, excluding dividends. Meanwhile, the FTSE All-Share has returned closer to 6% per annum. Including dividends these returns would be closer to 10%.

And remember, these returns exclude the impact of dividend reinvestment. According to my figures, a £1000 investment in the FTSE All-share, yielding 3% per annum, with capital growth of 5.9% would turn £1,000 into £8,200 over a period of 30 years.

Of course, this is excluding costs, but there are some very low cost trackers out there for you to take advantage of. In particular, BlackRock 100 UK Equity TrackerFidelity Index UK charges 0.09% and the db x-trackers FTSE 100 UCITS ETF (LSE: XUKX) charges a lowly 0.09%.

For the FTSE All-Share, Vanguard FTSE UK Equity Index charges 0.15%, BlackRock UK Equity Tracker offers index replication for 0.16% and the Legal & General Tracker Trust charges 0.16%.

Rupert Hargreaves has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Middle-aged white man pulling an aggrieved face while looking at a screen
Market Movers

Down 7%! Why on earth are Imperial Brands shares plummeting today?

Imperial Brands shares are in freefall after a negative reception to fresh trading news. Is the party finally over for…

Read more »

Rear View Of Woman Holding Man Hand during travel in cappadocia
Investing Articles

With a P/E under 7, this value stock looks far too cheap at 101p

This writer reckons value stock Hostelworld (LSE:HSW) looks dirt-cheap as it gets dividends flowing again and builds a social travel…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Investing For Beginners

Down 30% in 6 months, I think there’s a big catch to this insanely cheap stock

Jon Smith talks through why careful research is needed when trying to assess if a cheap stock is worth buying…

Read more »

Investing Articles

£5,000 invested in National Grid shares 5 years ago is now worth…

Andrew Mackie takes a closer look at National Grid shares and why short-term market weakness could be missing a powerful…

Read more »

DIVIDEND YIELD text written on a notebook with chart
Investing Articles

How big does an ISA need to be to aim for a £1,500 monthly second income?

Harvey Jones shows how building a balanced portfolio of FTSE 100 dividend stocks can produce a high-and-rising second income in…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

£20,000 invested in BP shares 1 year ago is now worth…

BP shares have rocketed in the past 12 months, yet analysts think the real growth story is only just beginning,…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

A 6.8% forecast yield! 1 often-overlooked FTSE 100 income stock to buy today?

This income stock offers a high forecast yield and strengthening momentum, yet many investors overlook it — creating a rare…

Read more »

GSK scientist holding lab syringe
Investing Articles

GSK’s share price is under £22, but with a ‘fair value’ much higher, is it time for me to buy more right now? 

GSK’s share price rose over the last year, but a huge gap remains between its price and fair value —…

Read more »